Loading clinical trials...
Loading clinical trials...
Oral Lactoferrin Prophylaxis to Prevent Sepsis and Necrotising Enterocolitis of Very Low Birth Weight Neonates in Neonatal Intensive Care Unit and Effect on T-regulatory Cells.
The aim of the study is to evaluate whether oral administration of 200 mg/day lactoferrin (LF) to very low birth weight infants reduces late onset sepsis and necrotising enterocolitis and the effect of LF on regulatory T cells.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Ankara University School of Medicine Department of Pediatrics, NICU
Ankara, Turkey (Türkiye)
Start Date
December 1, 2009
Primary Completion Date
January 1, 2011
Completion Date
December 1, 2011
Last Updated
August 26, 2014
60
ACTUAL participants
Lactoferrin (bovine origin)
DIETARY_SUPPLEMENT
Lead Sponsor
Ankara University
NCT06092463
NCT06965842
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions